Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Current and Projected Market Size of the Netupitant-Palonosetron FDC Industry?

The market size for the fixed dose combination of netupitant-palonosetron has seen substantial growth in the past years. It’s slated to rise from $351.07 billion in 2024 to $384.5 billion in 2025, with a compound annual growth rate (CAGR) of 9.5%. The previous period’s growth is credited to the escalating utilization of combined antiemetic treatments, heightened consciousness among oncologists, a rise in cancer instances, mounting clinical proofs that vouch for its efficiency and safety, and growing accessibility to cancer therapies in emerging markets.

In the forthcoming years, the market size for the netupitant-palonosetron fixed dose combination (fdc) is anticipated to experience robust growth, escalating to $555.45 billion in 2029 at a compound annual growth rate (CAGR) of 9.6%. This growth during the projected period is credited to an increasing emphasis on enhancing the quality of life during chemotherapy sessions, a rising inclination towards home-based chemotherapy treatment options, a growing demand for user-friendly antiemetic regimens and effective antiemetic therapies, and an increasing preference for oral fixed-dose combinations over polypharmacy. Key trends for the upcoming forecasting period encompass innovative therapeutic progressions, advanced formulations with dual action, enhancements in formulation propelled by technology, the creation of orally disintegrating dosage forms, and novelty in controlling emesis for multiple days.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24617&type=smp

#Which Factors Are Currently Driving The Growth Of The Netupitant-Palonosetron FDC Market?

The anticipated rise in cancer cases is likely to catalyze the expansion of the netupitant-palonosetron fixed-dose combination (FDC) market. Cancer refers to a range of illnesses characterized by unchecked increase and dissemination of anomalous cells within the body. Lifestyle factors such as unhealthy eating habits, tobacco use, lack of physical activity, and excessive alcohol intake are contributing to the increasing cancer cases. The combination of two potent anti-emetic agents in netupitant-palonosetron fixed-dose combination (FDC) contributes to enhanced cancer care by mitigating both immediate and delayed chemotherapy-induced sickness and throwing up. It increases patient satisfaction and treatment adherence, promoting superior overall results in healthcare. For example, data from the Australian Institute of Health and Welfare, a government institution in Australia, revealed that cancer cases diagnosed in Australia hit 160,570 in 2022 in July 2024, registering an increase of 3,789 cases from 156,781 in 2021. As such, the escalating incidence of cancer is propelling the expansion of the netupitant-palonosetron fixed-dose combination (FDC) market. The growing appetite for oral medications is also expected to fuel the growth of the netupitant-palonosetron fixed-dose combination (FDC) market. Oral medications are those taken via the mouth and assimilated through the digestive system to cure or prevent diverse health problems. The surging demand for these drugs emanates from their ease of use and convenience, enabling patients to self-administer without professional aid. The efficiency of oral medications is enhanced by netupitant-palonosetron FDC, which mitigates nausea and vomiting, subsequently enhancing treatment compliance and outcomes for patients. According to the US-based government authority, the Centers for Disease Control and Prevention, the distribution of oral antivirals surged by 57%, from 643 per 100,000 individuals between April 24 and May 21, 2022, to 1,012 per 100,000 individuals between July 31 and August 28, 2022. Therefore, the increasing demand for oral medications is driving the expansion of the netupitant-palonosetron fixed-dose combination (FDC) market.

How Is The Global Netupitant-Palonosetron FDC Market Structured In Terms Of Segments?

The netupitant-palonosetron fdc market covered in this report is segmented –

1) By Product Type: Netupitant, Palonosetron, Fixed Dose Combination (FDC)

2) By Route Of Administration: Oral Administration, Intravenous (IV) Administration, Sublingual Administration

3) By Application: Chemotherapy Induced Nausea And Vomiting (CINV), Postoperative Nausea And Vomiting (PONV), General Nausea Management

4) By Distribution Channel: Hospitals, Retail Pharmacies, Online Pharmacies, Specialty Clinics

Subsegments:

1) By Netupitant: Oral Netupitant, Injectable Netupitant

2) By Palonosetron: Oral Palonosetron, Injectable Palonosetron

3) By Fixed Dose Combination: Oral Fixed Dose Combination, Intravenou Fixed Dose Combination

What Trends Are Currently Influencing Growth In The Netupitant-Palonosetron FDC Market?

Leading firms in the netupitant-palonosetron fixed dose combination (FDC) sector are prioritizing the creation of advanced product formulations such as ready-to-use intravenous formulations. These efforts aim to increase treatment effectiveness and patient convenience. Ready-to-use intravenous formulations are sterile drug solutions that are pre-prepared, eliminating the requirement for dilution or mixing. This enhances the ease of administration and minimizes the risk of preparation errors for netupitant-palonosetron fixed dose combination (FDC). An example of this is the June 2024 launch of AKYNZEO (fosnetupitant/palonosetron) injection by Helsinn Group, a pharmaceutical company based in Switzerland. This ready-to-use vial is available in the United States and is carefully crafted to streamline both the preparation and administration processes for healthcare providers in clinical settings. The injection does not need reconstitution or dilution and comes with an integrated hanging strap for direct infusion from the vial.

Who Are The Main Participants Shaping The Netupitant-Palonosetron FDC Market Landscape?

Major companies operating in the netupitant-palonosetron fdc market are Taiho PharmaceuticalTaiho Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd, Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Limited, Zhejiang Tiantai Pharmaceutical Co. Ltd., Hikma Pharmaceuticals PLC, Glenmark Pharmaceuticals Limited, Helsinn Group, Heron Therapeutics Inc., Metrochem API Private Limited, Mundipharma Pty Ltd, Guangzhou Tosun Pharmaceutical Co. Ltd., Tesaro Inc., Accord Healthcare Ltd., Century Pharmaceuticals Ltd., Specialised Therapeutics Australia Pty Ltd., Aark Pharmaceuticals Ltd., Chemicea Pharmaceuticals Pvt. Ltd., Teva Pharmaceutical Industries Ltd.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/netupitant-palonosetron-fdc-global-market-report

Which Region Currently Holds The Largest Share In The Netupitant-Palonosetron FDC Market?

North America was the largest region in the netupitant-palonosetron fixed dose combination (FDC) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the netupitant-palonosetron fdc market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24617&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model